KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Sarepta Therapeutics (SRPT) over the last 14 years, with Q3 2025 value amounting to $650876.0.

  • Sarepta Therapeutics' Treasury Shares changed N/A to $650876.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $650876.0, marking a year-over-year change of. This contributed to the annual value of $2.2 million for FY2023, which is 2245.65% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Treasury Shares stood at $25.3 million for Q3 2025.
  • In the past 5 years, Sarepta Therapeutics' Treasury Shares ranged from a high of $2.2 million in Q4 2023 and a low of -$651000.0 during Q2 2025
  • Its 4-year average for Treasury Shares is $1.1 million, with a median of $1.3 million in 2021.
  • As far as peak fluctuations go, Sarepta Therapeutics' Treasury Shares surged by 3939.77% in 2021, and later soared by 2245.65% in 2023.
  • Over the past 4 years, Sarepta Therapeutics' Treasury Shares (Quarter) stood at $1.3 million in 2021, then soared by 38.59% to $1.8 million in 2022, then rose by 22.46% to $2.2 million in 2023, then tumbled by 70.95% to $650876.0 in 2025.
  • Its Treasury Shares stands at $650876.0 for Q3 2025, versus -$651000.0 for Q2 2025 and $2.2 million for Q4 2023.